Searchable abstracts of presentations at key conferences in endocrinology

ea0062p62 | Poster Presentations | EU2019

A case of a TSH-secreting pituitary macroadenoma in a previously well thirty year old woman

Golding Jonathan , Canagon Sara , Norris John , Chakera Ali

Case History: A thirty year old female presented to hospital after a first seizure. She had no significant past medical history. She had a one week history of recurrent frontal headaches and had noticed irregular periods. There were no clinical features of acromegaly. CT and MRI brain imaging showed a 5 cm mass arising from the pituitary fossa, extending into the suprasellar cistern and anterior cranial fossa. There was evidence of mass effect on the optic nerves and optic chi...

ea0049gp63 | Developmental & Protein Endocrinology | ECE2017

Does the loss of RAD52 in PC contribute to resistance to antiandrogen therapy?

Alfaqih Mahmoud A. , Chang Ching yi , Norris John , McDonnell Donald P.

Recent statistics indicate that prostate cancer (PC) is the most frequent cancer in men worldwide and is the leading cause of cancer death in men above 50 years of age. The Androgen receptor (AR), a member of the superfamily of nuclear hormone receptors, plays a well-established role in the development and progression of the disease. PC localized to the prostate is commonly treated with surgical removal of the gland and is often associated with a favorable outcome. However, me...

ea0074ncc5 | Highlighted Cases | SFENCC2021

Grave’s orbitopathy – Metastatic breast cancer presenting as orbitopathy, not previously recorded in the endocrine literature

Isand Kristina , Wass John , Norris Jonathan , Heleen Noor Inger

Case history: A 67-year-old lady was referred to an endocrinologist for autoimmune hypothyroidism diagnosed in 2004. A treatment combination of levothyroxine and liothyronine was used. She had a history of recurrent metastatic ER-positive HER-2 negative lobular breast cancer with liver and bony metastatic involvement. She commenced with Letrozole (aromatase inhibitor) and Palbociclib (CDK inhibitor), later Fulvestrant (antioestrogen) and Crizotinib (tyrosine kinase inhibitor)....